ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
Healthcare
$7.70 -0.75%
-$0.07 today
- Market cap
- $800.27M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
52W Low $7.23High $14.93
Volume 1.07M
Average 1.91M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$143.00M
FY 2025 · Annual
Net Income
-$129.47M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| 37.95M | 39.66M | 51.45M | 69.73M | 87.79M | |
| 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Earnings Waterfall · TTM
NASDAQ:ORIC · Revenue to Net Income
Key Ratios
EPS$-1.44
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$135.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.44, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 |
How much revenue does ORIC generate?
ORIC Pharmaceuticals, Inc. (ORIC) reported $0.00 of revenue in fiscal 2025.
Is ORIC profitable?
ORIC Pharmaceuticals, Inc. (ORIC) reported -$129.47M of net income.
Continue the stock analysis
Jump to another research area for this company.